NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States.
Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging.
We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China.
Type | Public | |
Founded | 2000 | |
HQ | Emeryville, CA, US | Map |
Website | novabay.com |
USD | |
---|---|
Revenue (Q2, 2020) | 4.0m |
Gross profit (Q2, 2020) | 1.9m |
Gross profit margin (Q2, 2020), % | 48.8% |
Net income (Q2, 2020) | (4.5m) |
EBIT (Q2, 2020) | (1.1m) |
Market capitalization (8-Jan-2021) | 32.3m |
Closing stock price (8-Jan-2021) | 0.8 |
Cash (30-Jun-2020) | 8.8m |
EV | 25.0m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.5m | 2.8m | 1.3m | 871.0k | 3.6m | 957.0k | 831.0k | 1.1m | 100.0k | 102.0k | 62.0k | 46.0k | 1.0m | 1.2m | 1.7m | 2.7m | 3.4m | 3.7m | 4.1m | 4.1m | 2.9m | 2.8m | 3.1m | 1.5m | 1.8m | 1.6m | 1.9m | 4.0m |
Cost of goods sold | 22.0k | 16.0k | 43.0k | 130.0k | 18.0k | 42.0k | 148.0k | 253.0k | 269.0k | 479.0k | 566.0k | 588.0k | 698.0k | 521.0k | 251.0k | 479.0k | 332.0k | 341.0k | 403.0k | 401.0k | 581.0k | 2.0m | ||||||
Gross profit | 935.0k | 815.0k | 1.1m | (30.0k) | 84.0k | 20.0k | (102.0k) | 755.0k | 931.0k | 2.2m | 2.9m | 3.1m | 3.4m | 3.6m | 2.7m | 2.3m | 2.8m | 1.2m | 1.4m | 1.2m | 1.3m | 1.9m | ||||||
Gross profit Margin, % | 98% | 98% | 96% | (30%) | 82% | 32% | (222%) | 75% | 78% | 82% | 84% | 84% | 83% | 87% | 91% | 83% | 89% | 77% | 77% | 75% | 69% | 49% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 8.0m | 12.4m | 6.1m | 4.7m | 7.2m | 8.4m | 6.6m | 6.9m | 10.3m | 7.8m | 7.9m | 5.6m | 7.2m | 3.4m | 1.4m | 3.5m | 9.4m | 7.4m | 5.7m | 6.1m | 8.3m | 6.8m | 5.2m | 2.9m | 3.7m | 9.0m | 5.7m | 8.8m |
Accounts Receivable | 3.6m | 1.8m | 1.0m | 9.0k | 126.0k | 916.0k | 112.0k | 272.0k | 260.0k | 440.0k | 364.0k | 283.0k | 389.0k | 543.0k | 1.5m | 2.1m | 2.3m | 3.6m | 2.2m | 2.2m | 2.0m | 2.6m | 2.4m | 1.5m | 1.5m | 952.0k | 1.4m | |
Prepaid Expenses | 586.0k | 289.0k | 427.0k | 506.0k | 508.0k | 365.0k | 427.0k | 330.0k | 794.0k | 656.0k | 514.0k | 1.2m | 597.0k | 668.0k | 474.0k | 1.8m | 1.0m | 972.0k | 1.0m | 1.8m | 1.6m | 1.3m | 1.5m | 1.6m | 1.1m | 662.0k | 1.1m | |
Inventories | 61.0k | 48.0k | 63.0k | 155.0k | 218.0k | 405.0k | 492.0k | 1.5m | 1.6m | 1.2m | 1.1m | 1.1m | 765.0k | 672.0k | 599.0k | 479.0k | 317.0k | 390.0k | 302.0k | 664.0k | 838.0k | 552.0k | 626.0k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (5.1m) | (7.0m) | (16.0m) | (15.2m) | (19.0m) | (13.2m) | (7.4m) | (6.5m) | (9.7m) |
Depreciation and Amortization | 425.0k | 341.0k | 314.0k | 232.0k | 164.0k | 114.0k | 95.0k | 266.0k | 65.0k |
Inventories | (23.0k) | (208.0k) | (451.0k) | (751.0k) | 472.0k | 369.0k | 198.0k | (212.0k) | |
Accounts Payable | 345.0k | 665.0k | 1.4m | (252.0k) | 1.7m | (2.2m) | (260.0k) | 516.0k | (1.8m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (1.6m) | (1.5m) | (2.5m) | (4.8m) | (4.7m) | (4.0m) | (8.1m) | (11.9m) | (3.6m) | (6.5m) | (10.7m) | (4.6m) | (9.5m) | (14.8m) | (5.1m) | (7.8m) | (11.5m) | (4.0m) | (5.7m) | (8.2m) | (2.1m) | (3.7m) | (5.3m) | (4.2m) | (6.7m) | (7.0m) | (1.6m) | (6.1m) |
Depreciation and Amortization | 216.0k | 321.0k | 91.0k | 174.0k | 256.0k | 81.0k | 161.0k | 240.0k | 70.0k | 141.0k | 185.0k | 41.0k | 82.0k | 123.0k | 40.0k | 67.0k | 98.0k | 18.0k | 36.0k | 54.0k | 41.0k | 127.0k | 219.0k | 17.0k | 33.0k | 50.0k | 14.0k | 28.0k |
Inventories | (38.0k) | (25.0k) | (40.0k) | 76.0k | 12.0k | (175.0k) | 29.0k | (871.0k) | (1.0m) | 144.0k | 193.0k | 261.0k | 108.0k | 200.0k | 273.0k | 160.0k | 89.0k | (21.0k) | (383.0k) | (558.0k) | (59.0k) | (134.0k) | ||||||
Accounts Payable | 287.0k | (167.0k) | 167.0k | 785.0k | 1.3m | (222.0k) | 400.0k | 959.0k | (1.2m) | (1.4m) | (1.1m) | 357.0k | (286.0k) | 1.1m | (1.7m) | (2.1m) | 234.0k | 390.0k | 602.0k | (161.0k) | (327.0k) | (56.0k) | (521.0k) | (1.4m) | (1.6m) | (175.0k) | 473.0k |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.6 x |
NovaBay Pharmaceuticals has 35 Twitter Followers. The number of followers has decreased 1.1% month over month and decreased 1.7% quarter over quarter
When was NovaBay Pharmaceuticals founded?
NovaBay Pharmaceuticals was founded in 2000.
Who are NovaBay Pharmaceuticals key executives?
NovaBay Pharmaceuticals's key executives are Paul E. Freiman, Justin Hall and Andrew Jones.
How many employees does NovaBay Pharmaceuticals have?
NovaBay Pharmaceuticals has 33 employees.
What is NovaBay Pharmaceuticals revenue?
Latest NovaBay Pharmaceuticals annual revenue is $6.6 m.
What is NovaBay Pharmaceuticals revenue per employee?
Latest NovaBay Pharmaceuticals revenue per employee is $200 k.
Who are NovaBay Pharmaceuticals competitors?
Competitors of NovaBay Pharmaceuticals include Bird Rock Bio, SmartZyme and Patheon.
Where is NovaBay Pharmaceuticals headquarters?
NovaBay Pharmaceuticals headquarters is located at 2000 Powell St #1150, Emeryville.
Where are NovaBay Pharmaceuticals offices?
NovaBay Pharmaceuticals has an office in Emeryville.
How many offices does NovaBay Pharmaceuticals have?
NovaBay Pharmaceuticals has 1 office.
Receive alerts for 300+ data fields across thousands of companies